Radicle GI Health 24: A Study of Health and Wellness Products on GI Health and Related Health Outcomes

NCT06376695 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4607

Last updated 2025-10-02

No results posted yet for this study

Summary

A randomized, double-blind, placebo-controlled study assessing the impact of health and wellness products on GI health and related health outcomes

Conditions

Interventions

DIETARY_SUPPLEMENT

Radicle GI Health Placebo Control Form 1

Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.

DIETARY_SUPPLEMENT

Radicle GI Health Active Study Product 1.1 Usage

Participants will use their Radicle GI Health Active Study Product 1.1 as directed for a period of 6 weeks.

DIETARY_SUPPLEMENT

Radicle GI Health Placebo Control Form 2

Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.

DIETARY_SUPPLEMENT

Radicle GI Health Active Study Product 2.1 Usage

Participants will use their Radicle GI Health Active Study Product 2.1 as directed for a period of 6 weeks.

DIETARY_SUPPLEMENT

Radicle GI Health Placebo Control Form 3

Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.

DIETARY_SUPPLEMENT

Radicle GI Health Active Study Product 3.1 Usage

Participants will use their Radicle GI Health Active Study Product 3.1 as directed for a period of 6 weeks.

DIETARY_SUPPLEMENT

Radicle GI Health Placebo Control Form 4

Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.

DIETARY_SUPPLEMENT

Radicle GI Health Active Study Product 4.1 Usage

Participants will use their Radicle GI Health Active Study Product 4.1 as directed for a period of 6 weeks.

DIETARY_SUPPLEMENT

Radicle GI Health Placebo Control Form 5

Participants will use their Placebo Control Form 5 as directed for a period of 6 weeks.

DIETARY_SUPPLEMENT

Radicle GI Health Active Study Product 5.1 Usage

Participants will use their Radicle GI Health Active Study Product 5.1 as directed for a period of 6 weeks.

DIETARY_SUPPLEMENT

Radicle GI Health Placebo Control Form 7

Participants will use their Placebo Control Form 7 as directed for a period of 6 weeks.

DIETARY_SUPPLEMENT

Radicle GI Health Active Study Product 7.1 Usage

Participants will use their Radicle GI Health Active Study Product 7.1 as directed for a period of 6 weeks.

DIETARY_SUPPLEMENT

Radicle GI Health Placebo Control 7.2

Participants will use their Placebo Control 7.2 as directed for a period of 6 weeks.

DIETARY_SUPPLEMENT

Radicle GI Health Active Study Product 7.2.1 Usage

Participants will use their Radicle GI Health Active Study Product 7.2.1 as directed for a period of 6 weeks.

DIETARY_SUPPLEMENT

Radicle GI Health Placebo Control 7.3.0

Participants will use their Placebo Control 7.3 as directed for a period of 6 weeks.

DIETARY_SUPPLEMENT

Radicle GI Health Active Study Product 7.3.1 Usage

Participants will use their Radicle GI Health Active Study Product 7.3.1 as directed for a period of 6 weeks.

DIETARY_SUPPLEMENT

Radicle GI Health Placebo Control 7.4.0

Participants will use their Placebo Control 7.4 as directed for a period of 6 weeks.

DIETARY_SUPPLEMENT

Radicle GI Health Active Study Product 7.4.1 Usage

Participants will use their Radicle GI Health Active Study Product 7.4.1 as directed for a period of 6 weeks.

Sponsors & Collaborators

  • Radicle Science

    lead INDUSTRY

Principal Investigators

  • Emily K. Pauli, PharmD · Radicle Science Inc.

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
105 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-29
Primary Completion
2025-06-05
Completion
2025-06-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06376695 on ClinicalTrials.gov